Skip to content
DataLookout
Menu

NCT07300085

A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 4 → 15 locations
  2. Notable Enrollment reopened
    • Study sites: 4 to 2
  3. Notable Eligibility criteria expanded, about 5 words
    • Secondary endpoints: details revised at 3 of 4 entries
  4. Notable Enrollment increased: 100 → 710 participantsv3 Show 8 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria shortened, about 1,424 words
    • Study sites: 2 to 4
    • Primary and study completion dates: Dec 2026 to Dec 31, 2026
    • Interventions: CD388 Injection (Combination Product), Fluzone HD influenza vaccine (Biological), Placebo (Combination Product) to Fluzone® High-Dose (HD) influenza vaccine (Biological), MK-1406 Injection (Combination Product), Placebo (Combination Product)
    • Secondary endpoints: 1 to 4
    • Study description shortened, about 17 words
    • Study title expanded, about 1 word
  5. Notable Sponsor changed: Cidara Therapeutics Inc. to Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
    • Primary and study completion dates: May 2026 to Dec 2026
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 2 of 2 sites
    v2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Geometric Mean of Hemagglutinin Inhibition (HAI) Titers Against the Influenza Strains Contained in the Vaccine Among Participants Receiving Concomitant Fluzone® High-Dose (HD) and MK-1406 Compared to Participants Who Receive Fluzone® HD and Placebo
Timeframe: Predose (Day 1), Day 15 and Day 29
Percentage of Participants with Seroconversion Rates against the Influenza Strains Contained in the Vaccine Among Participants Receiving Concomitant Fluzone® HD and MK-1406 Compared to Participants Who Receive Fluzone® HD and Placebo
Timeframe: Predose (Day 1), Day 15 and Day 29

Secondary (4)

Percentage of participants with ≥1 Adverse Event (AE)
Percentage of Participants Who Discontinued from the Study Due to an Adverse Event
Percentage of Participants with a Solicited Injection-site Adverse Event
Percentage of Participants with a Solicited Systemic Adverse Event

Arms and interventions

Fluzone® High-Dose (HD) plus MK-1406Experimental

Participants will receive open-label Fluzone® HD influenza vaccine by intramuscular (IM) injection plus MK-1406 by subcutaneous (SC) injection on Day 1.

Fluzone® HD plus PlaceboPlacebo comparator

Participants will receive open-label Fluzone® HD influenza vaccine by IM injection plus placebo by SC injection on Day 1.

Biologicals: Fluzone® High-Dose (HD) influenza vaccine

Combination products: MK-1406 Injection, Placebo

Sites

15 sites in 1 country